{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:08:57Z","timestamp":1785553737362,"version":"3.56.0"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Brodalumab, a fully human monoclonal immunoglobulin IgG2 antibody that binds the human interleukin 17 receptor subunit A, is available for the treatment of moderate\u2010to\u2010severe plaque psoriasis in Europe since September 2017, but so far there are only a few studies on its use in real\u2010world conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the management of moderate\u2010to\u2010severe psoriasis with brodalumab 210\u2009mg in daily practice after 12 and 52\u2009weeks (W). In addition, patient profiles and treatment pathways are described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>LIBERO is a prospective, multicenter, non\u2010interventional study including adult patients with plaque psoriasis treated with brodalumab 210\u2009mg.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 638 patients (65% male, mean age: 49.3\u2009\u00b1\u200914.4\u2009years) from 148 sites in Germany were enrolled. The majority suffered from severe (51.1%) or very severe (13.1%) psoriasis according to physician global assessment (PGA0\u20105). When starting with brodalumab, 58.5% were biologic na\u00efve and 41.5% were previously treated with another biologic, mainly adalimumab (18.5%) and secukinumab (17.9%). About 74.0% of patients met the primary endpoint of an absolute PASI \u22643 at ~W12 (<jats:italic>n<\/jats:italic>\u2009=\u2009618, LOCF). The mean PASI was reduced significantly as of ~W2 from 17.2 (\u00b111.7) to 9.7 (\u00b18.8) and improved further to 3.3 (\u00b16.3) at ~W12 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). At ~W52 85.5% of patients reached a PGA0\/1\u2010response (primary endpoint) and 54.1% patients were assessed as completely clear (PGA0) (both <jats:italic>n<\/jats:italic>\u2009=\u2009399, as observed). Effectiveness of brodalumab was confirmed in relevant subgroup analysis by previous treatment regimen. Most frequently reported adverse events were nasopharyngitis (4.6%), psoriasis (4.6%) and arthralgia (4.1%), new safety signals were not detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This representative, non\u2010interventional study confirms the short\u2010 and long\u2010term effectiveness and safety profile of brodalumab in the management of psoriasis in daily practice as well as in relevant treatment pathways.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19974","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T11:15:46Z","timestamp":1712229346000},"page":"2156-2166","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of moderate to severe psoriasis with brodalumab\u2014Real\u2010world evidence from the <scp>LIBERO<\/scp> study"],"prefix":"10.1111","volume":"38","author":[{"given":"R.","family":"von Kiedrowski","sequence":"first","affiliation":[{"name":"Medical Study &amp; Service Selters GmbH  Selters (Westerwald) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hinz","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Hautgesundheit  Neuwied Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mauer","sequence":"additional","affiliation":[{"name":"Hautarztpraxis  Bad Kreuznach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schwinn","sequence":"additional","affiliation":[{"name":"Hautarztpraxis  Memmingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Timmel","sequence":"additional","affiliation":[{"name":"Hautzentrum R\u00fcgen  Bergen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Hutt","sequence":"additional","affiliation":[{"name":"LEO Pharma GmbH  Neu\u2010Isenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"M.","family":"Augustin","sequence":"additional","affiliation":[{"name":"German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg\u2010Eppendorf (UKE)  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"issue":"7","key":"e_1_2_11_2_1","first-page":"675","article-title":"Zytokine der IL\u201017\u2010Familie bei der psoriasis","volume":"18","author":"Lauffer F","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0092-3"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0500-9"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1993"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16931"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15886"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2082354"},{"issue":"5","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ddg.13516","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update \u2010 short version part 1 \u2010 systemic treatment","volume":"16","author":"Nast A","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_11_12_1","unstructured":"Von KiedrowskiR DirschkaT Kr\u00e4hn\u2010SenftlebenG KurzenH OstendorfR QuistSR et\u00a0al.Empfehlungen f\u00fcr die ambulante Versorgung von Psoriasis vulgaris: Aktualisierter praxisnaher Behandlungspfad onkoderm e.V. Psoriasis aktuell 2019. [cited 2023 Aug 2]. Available from:https:\/\/onkoderm.de\/wp\u2010content\/uploads\/2022\/07\/onkoderm_Behandlungspfad_Psoriasis_2019_E3.pdf"},{"key":"e_1_2_11_13_1","unstructured":"SorbeC GrieseL K\u00fchlL KirstenN ReichK BoehnkeWH et\u00a0al.PsoBest: Aktueller Stand Profile und Auswirkungen auf die Gesundheitsversorgung durch das deutsche Psoriasisregister Poster presented at German Congress of Dermatology 2021. [cited 2022 Dec 11]. Available from:https:\/\/www.psobest.de\/wp\u2010content\/uploads\/2021\/06\/P221_PsoBest_Update.pdf"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16464"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00337-y"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15920"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.038"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00511-1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02065-w"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00602-z"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1743811"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.026"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00466-2"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00545-5"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16932"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.007"},{"issue":"4","key":"e_1_2_11_27_1","first-page":"354","article-title":"Long\u2010term skin clearance with Brodalumab in patients with psoriasis and inadequate response to prior biologics","volume":"21","author":"Lebwohl M","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15772"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15106"},{"key":"e_1_2_11_30_1","first-page":"1","article-title":"Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL\u201017A blocker \u2010 a retrospective multicenter study","volume":"32","author":"Kromer C","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.013"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01907-y"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00411-w"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15105"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.530"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1638788"},{"issue":"6","key":"e_1_2_11_37_1","first-page":"361","article-title":"Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review","volume":"104","author":"Koo J","year":"2019","journal-title":"Cutis"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T23:23:44Z","timestamp":1741735424000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/jdv.19974"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19974","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"2023-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}